益气活血中成药治疗心肌梗死随机对照试验的系统评价  

Systematic review of randomized controlled trials on treatment of myocardial infarction with YiqiHuoxue Chinese patent medicine

作　　者：张俊华[1] 商洪才[1] 张伯礼[1] 高秀梅[1] 项耀祖[1] 王辉[1] 曹红波[1] 任明[2] 

机构地区：[1]天津中医药大学中医药研究院 [2]省部共建方剂学教育部重点实验室,天津300193

出　　处：《中华中医药杂志》2008年第4期300-306,共7页China Journal of Traditional Chinese Medicine and Pharmacy

基　　金：国家科技攻关项目(No.2004BA716B01);国家自然科学基金项目(No.30600834);中国博士后科学基金(No.20070411156);

摘　　要：目的:评价益气活血中成药治疗心肌梗死的疗效和安全性。方法:通过检索Cochrane library、MEDLINE、EMBASE、CBM、CNKI和VIP等数据库(截至2006年11月),全面搜集有关益气活血中成药治疗心肌梗死的随机对照试验,文献质量评价参照Cochrane系统评价员手册。结果:有28篇文献被纳入评价,结局指标为心梗急性期病死率,冠状动脉再通率,再梗死发生率,三大并发症(心衰、休克、心律失常)的发生率,以及其他中间指标。由于纳入研究间临床异质性较大,没有进行定量合并分析,只做描述性分析。结论:由于纳入研究方案差异大、质量较低,加用益气活血中成药对心肌梗死的疗效尚缺乏可靠证据的支持,有待高质量的证据来验证。Objective： To assess the efficacy and safety of YiqiHuoxue preparations for the treatment of myocardial infarction （MI）. Methods： An extensive search including Cochrane library, Medline, Embase, CBM, CNKI and VIP was performed up to November 2006. Randomized controlled trials （RCTs） about YiqiHuoxue Chinese patent medicine for the treatment of MI were included irrespective of language. The quality of each trial was assessed according to the Cochrane Reviewers＇Handbook 4.2.6. Results： Twenty-eight RCTs were included in this review. The main outcomes were mortality, coronary artery recanalization, recurrent myocardial infarction, incidence of complications and other indirect outcomes. Because of the significant clinical heterogeneity between included trials, we just did descriptive analysis without meta-analysis. We couldn＇t get an affirmative conclusion that YiqiHuoxue preparations were useful for the treatment of MI. Conclusions： Because of low quality and significant heterogeneity of included trials, the efficacy of YiqiHuoxue Chinese patent medicine for the treatment of MI are still lack of sufficient evidence. Further studies are necessary.

关 键 词：中成药 益气活血 心肌梗死 系统评价 

分 类 号：R259[医药卫生—中西医结合]